{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:55:33Z","timestamp":1790571333644,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Precision Radiation Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with locally advanced head and neck squamous cell carcinoma (LA\u2010HNSCC) harboring high\u2010risk pathological features after radical surgery face high recurrence rates. This real\u2010world study evaluated the efficacy and safety of concurrent chemoradiotherapy (CCRT) with and without nimotuzumab in this postoperative population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with LA\u2010HNSCC who had high\u2010risk pathological features after surgery were stratified as follows: those with extranodal extension (ENE) or positive\/insufficient margins received nimotuzumab plus CCRT (NCCRT; extremely high risk), whereas those with other high\u2010risk factors (e.g., pT3\u20134 and N2\u20133) received CCRT alone (intermediate high risk). All patients underwent intensity\u2010modulated radiotherapy with weekly cisplatin. Overall survival (OS) was the primary endpoint, and event\u2010free survival (EFS) and safety were secondary endpoints. To minimize confounding bias due to non\u2010randomized treatment allocation, propensity\u2010score matching (PSM) was performed using a 1:1 nearest neighbor matching algorithm with a caliper width of 0.2 times the standard deviation of the propensity score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 75 patients were enrolled in this study (CCRT, n\u00a0=\u00a050; NCCRT,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a025). After PSM, 22 well\u2010balanced pairs were identified with no significant differences in baseline characteristics between the two groups. The median follow\u2010up time was 29.80 months (95% confidence interval [\n                      <jats:italic>CI<\/jats:italic>\n                      ]: 25.83\u201333.77) in the CCRT group and 30.23 months (95%\n                      <jats:italic>CI<\/jats:italic>\n                      : 25.07\u201335.40) in the NCCRT group. In the overall cohort, the 2\u2010year EFS and OS rates were 74.1%\u00a0vs 60.6% and 85.6%\u00a0vs 83.6%, respectively. In the matched cohort, the 2\u2010year EFS and OS rates were 73.8%\u00a0vs 58.3% (log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.087) and 86.2%\u00a0vs 82.5% (log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.342), respectively. Univariate analysis revealed that the platelet\u2010to\u2010lymphocyte ratio (PLR) and hemoglobin\u2010albumin\u2010lymphocyte\u2010platelet (HALP) score were significantly associated with OS in the CCRT group (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.019 and\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.009, respectively). Treatment\u2010related adverse events were predominantly grades 1\u20132, including radiodermatitis, oral mucositis, and hematological toxicities, with no significant increase in severe toxicities in the NCCRT group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risk\u2010stratified adjuvant CCRT, with or without nimotuzumab, was associated with promising outcomes and acceptable safety in patients with high\u2010risk postoperative LA\u2010HNSCC. Thus, PLR and HALP may serve as candidate prognostic biomarkers for intermediate\u2010risk patients and warrant further validation. These findings are hypothesis\u2010generating and require confirmation in prospective randomized studies with dedicated control groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pro6.70099","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:11:46Z","timestamp":1790568706000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high\u2010risk patients with locally advanced head and neck squamous cell carcinoma post\u2010surgery: A real\u2010world study"],"prefix":"10.1002","author":[{"given":"Yuejia","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen\u2010Peking University\u2010Hong Kong University of Science and Technology (PKU\u2010HKUST) Medical Center  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen\u2010Peking University\u2010Hong Kong University of Science and Technology (PKU\u2010HKUST) Medical Center  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-5168","authenticated-orcid":false,"given":"Wenjuan","family":"Lai","sequence":"additional","affiliation":[{"name":"Nursing Department Peking University Shenzhen Hospital  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9625-0723","authenticated-orcid":false,"given":"Jingyun","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen\u2010Peking University\u2010Hong Kong University of Science and Technology (PKU\u2010HKUST) Medical Center  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3613-9413","authenticated-orcid":false,"given":"Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen\u2010Peking University\u2010Hong Kong University of Science and Technology (PKU\u2010HKUST) Medical Center  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peking University Shenzhen Hospital  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen\u2010Peking University\u2010Hong Kong University of Science and Technology (PKU\u2010HKUST) Medical Center  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Peking University Shenzhen Hospital  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-9305","authenticated-orcid":false,"given":"Gangling","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen\u2010Peking University\u2010Hong Kong University of Science and Technology (PKU\u2010HKUST) Medical Center  Shenzhen Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"2","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma","volume":"11","author":"Barsouk A","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1269863","article-title":"Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta\u2010analysis","volume":"14","author":"Wang H","year":"2023","journal-title":"Front Pharmacol"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0016"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12218"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106657"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae029"},{"issue":"11","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/jamaoncol.2025.3136","article-title":"Emerging EGFR\u2010Targeted Therapy in Head and Neck Cancer: a Review","volume":"11","author":"Hwang W","year":"2025","journal-title":"JAMA Oncol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102864"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106087"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9163"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01293"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx343"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00817"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096281982240117114819"},{"issue":"7","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.608","article-title":"Epidermal growth factor receptor\u2010targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real\u2010world study","volume":"5","author":"Zhang P","year":"2020","journal-title":"MedComm"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380428","article-title":"Nimotuzumab combined with radiotherapy\u00b1 chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a meta\u2010analysis of randomized controlled trials","volume":"14","author":"Guan M","year":"2024","journal-title":"Front Oncol"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1467306","article-title":"Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta\u2010analysis","volume":"15","author":"Liu C","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt555"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8820"},{"issue":"1","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"KEYNOTE\u2010689 Investigators. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer","volume":"393","author":"Uppaluri R","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.05.008"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101426"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2022.5186"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032641"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20279"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1596583","article-title":"Advances and challenges in immunotherapy in head and neck cancer","volume":"16","author":"Aboaid H","year":"2025","journal-title":"Front Immunol"},{"key":"e_1_2_12_28_1","unstructured":"IHN01 Trial: Adjuvant CRT remains standard as nimotuzumab fails to lift DFS\/OS in resected stage III\/IV HNSCC\u2014OncoDaily.https:\/\/oncodaily.com\/oncolibrary\/ihn01\u2010trial"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.016"},{"issue":"12","key":"e_1_2_12_30_1","first-page":"1474","article-title":"NRG Oncology RTOG 0920 Collaborating Team. Postoperative Radiotherapy \u00b1 Cetuximab for Intermediate\u2010Risk Head and Neck Cancer","volume":"43","author":"Machtay M","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70746"},{"issue":"1","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13014-022-02152-w","article-title":"Role of postoperative chemoradiotherapy in head and neck cancer without positive margins or extracapsular extension: a propensity score\u2010matching analysis","volume":"17","author":"Liu ZQ","year":"2022","journal-title":"Radiat Oncol"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.10.023"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw428"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.4370"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.11.005"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483497","article-title":"Tertiary lymphoid structure\u2010related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma","volume":"15","author":"Wu F","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.radonc.2017.08.023","article-title":"The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy","volume":"125","author":"Cox S","year":"2017","journal-title":"Radiother Oncol"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152707"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27372"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1279733","article-title":"Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China","volume":"14","author":"Xu J","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1186\/s12903-024-05026-7","article-title":"Prognostic value of platelet\u2010to\u2010lymphocyte ratio in patients with oral squamous cell carcinoma: a systematic review and meta\u2010analysis","volume":"24","author":"Huang L","year":"2024","journal-title":"BMC Oral Health"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1378762","article-title":"Sarcopenia accompanied by systemic inflammation can predict clinical outcomes in patients with head and neck cancer undergoing curative therapy","volume":"14","author":"Kasahara K","year":"2024","journal-title":"Front Oncol"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28367"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16213"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26635"}],"container-title":["Precision Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pro6.70099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pro6.70099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pro6.70099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:11:49Z","timestamp":1790568709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pro6.70099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":45,"alternative-id":["10.1002\/pro6.70099"],"URL":"https:\/\/doi.org\/10.1002\/pro6.70099","archive":["Portico"],"relation":{},"ISSN":["2398-7324","2398-7324"],"issn-type":[{"value":"2398-7324","type":"print"},{"value":"2398-7324","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"2025-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"pro6.70099"}}